|By Marketwired .||
|May 16, 2014 07:35 AM EDT||
CEDAR KNOLLS, NJ -- (Marketwired) -- 05/16/14 -- MYOS Corporation (OTCBB: MYOS)
- Company Well Positioned to Achieve Significant Near-Term Milestones by Year End
- Research and Development Programs Exploring Fortetropin as Potential Treatment Option in Muscle Health and Sarcopenia Progressing in Multiple Clinical Studies
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"), announced today its financial results for the first quarter ended March 31, 2014 and provided highlights of the Company's recent progress and anticipated near-term research and development milestones for Fortetropin (also known as MYO-T12®), the first clinically proven natural myostatin inhibitor.
"Since the commercial launch of our first Fortetropin-powered bionutrition product, MYO-X, the Company has successfully created a solid growth and revenue engine, with total net revenues since inception approaching $6 million. We see our growing bionutrition revenues as an important means of accelerating investment in research and development. The Company is leveraging the expertise developed in advancing its bionutrition business to build a biotherapeutics portfolio of small molecules and other compounds which can be applied to the increasingly important clinical conditions in muscle health," said Robert J. Hariri, M.D., Ph.D., Chairman of the Board of MYOS. "During the first quarter we enhanced our commitment to our clinical research by strengthening our management team with a highly experienced Chief Medical Officer. We also initiated two additional clinical studies to further evaluate the effects of Fortetropin on myostatin inhibition in an effort to explore potential opportunities for expansion of our age-management pipeline. We believe that our team's continued dedication to our emerging muscle health therapeutic development program will enable MYOS to provide innovative solutions for multiple potential indications including sarcopenia, cachexia and age-associated muscle loss treatments in age-management."
FIRST QUARTER AND RECENT HIGHLIGHTS
- Reported first quarter 2014 net revenues of $1.55 million, an increase of 457% compared to the first quarter of 2013;
- Initiated a clinical study on Fortetropin's effect on skeletal muscle mass and strength in resistance-trained male subjects;
- Sponsored the upcoming Cancer Cachexia 2014 conference highlighting evolving mechanisms and therapies for treating debilitating muscle wasting syndrome related to cancer;
- Partnered with the Muscular Dystrophy Association (MDA) to raise funds and awareness for MDA's fight against degenerative muscle disease;
- Launched an educational portal on sarcopenia (www.sarcopeniacure.com) in conjunction with the Aging in Motion awareness campaign working to develop measures of clinical benefit for therapeutic products to treat sarcopenia;
- Presented lipidomic and proteomic characterization data on Fortetropin at the 2014 International Conference on Frailty and Sarcopenia Research and published an abstract in Journal of Frailty and Aging providing new insights into mechanisms by which Fortetropin may exert its beneficial effects on muscle;
- Initiated a clinical study on the effects of Fortetropin on blood chemistry, body mass index, waist circumference and other indices of muscle health in adult women;
- Appointed Wall Street investment veteran, Christopher Pechock, to the Board of Directors;
- Appointed experienced healthcare industry leader and clinician, Robert C. Ashton, Jr., M.D., as Chief Medical Officer; and
- Closed $4.735 million in private equity financing followed by a 1-for-50 reverse stock split.
- Clinical study data on Fortetropin in muscle and strength building activity in resistance-trained men expected by the end of the second quarter of 2014;
- Results of Fortetropin study in adult women expected early in the fourth quarter of 2014;
- Anticipate strategic collaboration for Fortetropin in age management market;
- Pre-clinical data on synergistic effects of myostatin inhibition on testosterone-mediated muscle growth expected in the second half of 2014;
- Formulation of liquid bionutrition Fortetropin product targeted for year-end; and
- Expansion of Board of Directors and Scientific Advisory Board anticipated to begin this year.
Peter Levy, MYOS' President and Chief Operating Officer added, "For the remainder of 2014 the MYOS team will be laser-focused on advancing our clinical pipeline and expanding Fortetropin in the age-management market and for additional therapeutic opportunities. The Company's patent strategy is sound and we will continue to rigorously pursue additional enhancements to our IP portfolio. By the end of the year we expect to have data from three studies, which we believe will be key to transforming the Company into its next phase of growth as a biotherapeutic leader in age-management and muscle health. We believe MYOS is well-positioned to capitalize on the strategic and commercial prospects for Foretropin and represents an opportunity for a broad group of investors attracted to small-to-mid cap companies interested in maximizing shareholder return."
FIRST QUARTER 2014 FINANCIAL SUMMARY
For the first quarter of 2014, the Company's net revenues were approximately $1,546,000 compared to net revenues of approximately $277,000 for the first quarter of 2013 and approximately $1,408,000 for the fourth quarter of 2013. Net revenues for the trailing twelve months was approximately $4,587,000.
Loss from operations was approximately $423,000 for the first quarter of 2014 compared to approximately $1,092,000 for the first quarter of 2013 and approximately $1,409,000 for the fourth quarter of 2013. Operating losses include the Company's investment in research and development activities in the first quarter of 2014 of approximately $434,000 compared to approximately $178,000 in the first quarter of 2013 and approximately $356,000 in the fourth quarter of 2013.
Net loss for the first quarter of 2014 was approximately $422,000 compared to approximately $1,090,000 for the first quarter of 2013 and approximately $1,408,000 for the fourth quarter of 2013. Basic and diluted net loss per share was $(0.16) for the first quarter of 2014 compared to $(0.47) for the first quarter of 2013 and $(0.64) for the fourth quarter of 2013. Per share results are based on weighted average shares outstanding of 2.703 million for the first quarter of 2014 compared to 2.295 million for the first quarter of 2013 and 2.217 million for the fourth quarter of 2013.
On a non-GAAP basis, net loss for the first quarter of 2014 was approximately $119,000 compared to approximately $736,000 for the first quarter of 2013. Non-GAAP basic and diluted net loss per share was $(0.04) for the first quarter of 2014 compared to $(0.32) for the first quarter of 2013. Non-GAAP net loss excludes stock-based compensation of approximately $303,000 for the first quarter of 2014 compared to approximately $354,000 for the first quarter of 2013.
The Company had cash of approximately $3,914,000 and total assets of $8,964,000 as of March 31, 2014 compared to cash of approximately $451,000 and total assets of $3,836,000 as of December 31, 2013.
In addition to the GAAP financial measures set forth in this press release, the Company has included non-GAAP net loss and non-GAAP basic and diluted net loss per share measures, which present results on a basis adjusted for certain items. Non-GAAP net loss and non-GAAP basic and diluted net loss per share are supplemental measures of our performance that are not required by, or presented in accordance with, GAAP. The Company uses these non-GAAP measures as key performance measures for the purpose of evaluating performance internally. The Company also believes these non-GAAP measures provide the Company's investors with useful information regarding the Company's historical operating results. These non-GAAP measures are not intended to replace the presentation of the Company's financial results in accordance with GAAP. Use of the terms non-GAAP net loss, and non-GAAP basic and diluted net loss per share may differ from similar measures reported by other companies. We define non-GAAP net loss as net loss adjusted for stock-based compensation and certain special charges that are otherwise included in GAAP net loss, including changes in fair value of warrants, amortization of deferred financing costs and impairment charges. Non-GAAP basic and diluted net loss per share refers to non-GAAP net loss divided by the weighted average number of basic and diluted shares outstanding. All of the non-GAAP measures discussed above are reconciled from their respective GAAP measures in the attached table "Reconciliation of GAAP to non-GAAP Net Loss" table set forth below.
A summary of key financial highlights for the three months ended March 31, 2014 and 2013 is as follows:
MYOS CORPORATION AND SUBSIDIARY (a development stage company) CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) April 11, 2007 (Inception Date) Three Months Ended March 31, to March 31, 2014 2013 2014 ------------- ------------- ------------- Net revenue $ 1,546,334 $ 277,374 $ 5,875,421 Cost of sales 404,774 126,989 2,838,896 ------------- ------------- ------------- Gross profit 1,141,560 150,385 3,036,525 Operating expenses 1,564,638 1,242,444 15,504,721 ------------- ------------- ------------- Loss from operations (423,078) (1,092,059) (12,468,196) Other Income (Expense) Interest income 1,189 1,865 14,068 Interest expense (14) - (827,044) Value of warrants in excess of the amount of additional paid-in capital received in the related private placement of restricted common stock - - (2,405,303) Change in fair value of warrants - - 4,085,570 Impairment charge - intellectual property - - (2,662,000) Amortization of deferred financing costs - - (80,000) Gain on forgiveness of debt - - 12,500 ------------- ------------- ------------- Total other income (expense) 1,175 1,865 (1,862,209) ------------- ------------- ------------- Net loss (421,903) (1,090,194) (14,330,405) ============= ============= ============= Weighted average number of common shares outstanding, basic and diluted 2,703,341 2,295,349 Basic and diluted net loss per share attributable to common stockholders $ (0.16) $ (0.47) ============= ============= MYOS CORPORATION AND SUBSIDIARY (a development stage company) CONSOLIDATED BALANCE SHEETS March 31, December 31, 2014 2013 ------------ ------------ (Unaudited) ASSETS Current assets Cash $ 3,913,705 $ 451,361 Accounts receivable 1,494,879 644,760 Inventories 860,572 142,430 Prepaid expenses and other current assets 319,580 215,128 ------------ ------------ Total current assets 6,588,736 1,453,679 Fixed assets, net of accumulated depreciation 336,398 344,366 Intellectual property 2,000,000 2,000,000 Intangible assets 38,652 38,377 ------------ ------------ Total assets $ 8,963,786 $ 3,836,422 ============ ============ LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 710,210 $ 184,685 Accrued expenses 369,578 311,704 ------------ ------------ Total current liabilities 1,079,788 496,389 ------------ ------------ Total liabilities 1,079,788 496,389 ------------ ------------ Commitments and contingencies Stockholders' equity Preferred stock, $.001 par value; 500,000 shares authorized; no shares issued and outstanding - - Common stock, $.001 par value, 6,000,000 shares authorized; 2,919,235 and 2,227,447 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively 2,918 2,227 Additional paid-in capital 22,211,485 17,246,308 Deficit accumulated during development stage (14,330,405) (13,908,502) ------------ ------------ Total stockholders' equity 7,883,998 3,340,033 ------------ ------------ Total liabilities and stockholders' equity $ 8,963,786 $ 3,836,422 ============ ============ MYOS CORPORATION AND SUBSIDIARY (a development stage company) Reconciliation of GAAP to Non-GAAP Net Loss (Unaudited) April 11, 2007 (Inception Date) Three Months Ended March 31, to March 31, 2014 2013 2014 ------------- ------------- ------------ GAAP - net loss (421,903) (1,090,194) (14,330,405) Stock-based compensation 302,911 354,372 4,985,132 Change in fair value of warrants - - (4,085,570) Amortization of deferred financing costs - - 80,000 Impairment charges - - 2,662,000 ------------- ------------- ------------ Non-GAAP - net loss (118,992) (735,822) (10,688,843) ------------- ------------- ------------ Weighted average number of common shares outstanding, basic and diluted 2,703,341 2,295,349 GAAP basic and diluted net loss per share $ (0.16) $ (0.47) Non-GAAP basic and diluted net loss per share $ (0.04) $ (0.32)
About MYOS Corporation
MYOS is a developmental stage bionutrition and biotherapeutics company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin (also known as MYO-T12®), the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company," visit www.myoscorp.com.
The Company's first commercial product MYO-X, powered by MYO-T12®, is distributed by Maximum Human Performance (MHP) and is currently available on popular retailer websites including www.mhpstrong.com, www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that MYO-X, as well as future products it envisions, will redefine existing standards for muscle health.
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of MYO-T12® and its effects on myostatin inhibition, including our research and development activities including the clinical studies described herein, product and customer demand, the continued growth of repeat purchases, market acceptance of our existing and future products, the ability to create new products through research and development, the continued growth in market expansion and revenue including the expansion into the age management market, the successful entry into new markets including the age management market, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the continued growth and expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail stores, the ability to strengthen our manufacturing relationships and reduce the costs of our products, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Investor and Media Contact:
Investor Relations and Corporate Communications
SYS-CON Events announced today that Catchpoint Systems, Inc., a provider of innovative web and infrastructure monitoring solutions, has been named “Silver Sponsor” of SYS-CON's DevOps Summit at 18th Cloud Expo New York, which will take place June 7-9, 2016, at the Javits Center in New York City, NY. Catchpoint is a leading Digital Performance Analytics company that provides unparalleled insight into customer-critical services to help consistently deliver an amazing customer experience. Designed...
Feb. 12, 2016 06:00 PM EST Reads: 402
Companies can harness IoT and predictive analytics to sustain business continuity; predict and manage site performance during emergencies; minimize expensive reactive maintenance; and forecast equipment and maintenance budgets and expenditures. Providing cost-effective, uninterrupted service is challenging, particularly for organizations with geographically dispersed operations.
Feb. 12, 2016 06:00 PM EST
When building large, cloud-based applications that operate at a high scale, it’s important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. “Fly two mistakes high” is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Lee...
Feb. 12, 2016 04:45 PM EST
DevOps is not just last year’s buzzword. Companies with DevOps practices are 2.5x more likely to exceed profitability, market share, and productivity goals. But how do you enable high performance? What can you do right now to start? Find out from DevOps experts including Gene Kim, co-author of "The Phoenix Project," and the Dynatrace Center of Excellence.
Feb. 12, 2016 04:30 PM EST
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
Feb. 12, 2016 04:30 PM EST Reads: 191
SYS-CON Events announced today that Column Technologies will exhibit at SYS-CON's @DevOpsSummit at Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Established in 1998, Column Technologies is a global technology solutions provider with over 400 employees, headquartered in the United States with offices in Canada, India, and the United Kingdom. Column Technologies provides “Best of Breed” technology solutions that automate the key DevOps principal...
Feb. 12, 2016 04:15 PM EST
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 ad...
Feb. 12, 2016 04:15 PM EST Reads: 425
Join us at Cloud Expo | @ThingsExpo 2016 – June 7-9 at the Javits Center in New York City and November 1-3 at the Santa Clara Convention Center in Santa Clara, CA – and deliver your unique message in a way that is striking and unforgettable by taking advantage of SYS-CON's unmatched high-impact, result-driven event / media packages.
Feb. 12, 2016 03:00 PM EST
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management...
Feb. 12, 2016 02:15 PM EST Reads: 449
There will be new vendors providing applications, middleware, and connected devices to support the thriving IoT ecosystem. This essentially means that electronic device manufacturers will also be in the software business. Many will be new to building embedded software or robust software. This creates an increased importance on software quality, particularly within the Industrial Internet of Things where business-critical applications are becoming dependent on products controlled by software. Qua...
Feb. 12, 2016 02:15 PM EST
As someone who has been dedicated to automation and Application Release Automation (ARA) technology for almost six years now, one of the most common questions I get asked regards Platform-as-a-Service (PaaS). Specifically, people want to know whether release automation is still needed when a PaaS is in place, and why. Isn't that what a PaaS provides? A solution to the deployment and runtime challenges of an application? Why would anyone using a PaaS then need an automation engine with workflow ...
Feb. 12, 2016 01:45 PM EST Reads: 231
With an estimated 50 billion devices connected to the Internet by 2020, several industries will begin to expand their capabilities for retaining end point data at the edge to better utilize the range of data types and sheer volume of M2M data generated by the Internet of Things. In his session at @ThingsExpo, Don DeLoach, CEO and President of Infobright, will discuss the infrastructures businesses will need to implement to handle this explosion of data by providing specific use cases for filte...
Feb. 12, 2016 01:00 PM EST Reads: 230
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies adopt disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advanced analytics, and DevO...
Feb. 12, 2016 12:30 PM EST Reads: 263
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Avere delivers a more modern architectural approach to storage that doesn’t require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbuilding of data centers ...
Feb. 12, 2016 12:30 PM EST Reads: 108
CIOs and those charged with running IT Operations are challenged to deliver secure, audited, and reliable compute environments for the applications and data for the business. Behind the scenes these tasks are often accomplished by following onerous time-consuming processes and often the management of these environments and processes will be outsourced to multiple IT service providers. In addition, the division of work is often siloed into traditional "towers" that are not well integrated for cro...
Feb. 12, 2016 12:00 PM EST Reads: 501